PFGTF: AI 评分 52/100 — AI 分析 (4月 2026)

Pacific Edge Limited is a cancer diagnostic company focused on early detection and management of cancers. Their key product, Cxbladder, is a non-invasive urine test for bladder cancer detection and management.

Key Facts: AI Score: 52/100 Sector: Healthcare

公司概况

概要：

Pacific Edge Limited, a New Zealand-based cancer diagnostics firm, specializes in genomic urine tests like Cxbladder for the early detection and management of bladder cancer across New Zealand, the United States, Australia, and Singapore. With a focus on non-invasive cancer detection, the company operates in the competitive medical diagnostics sector.

PFGTF是做什么的？

Pacific Edge Limited, founded in 2001 and headquartered in Dunedin, New Zealand, is a cancer diagnostic company dedicated to researching, developing, and commercializing innovative diagnostic and prognostic tools. The company's primary focus is on the early detection and management of various cancers, with a strong emphasis on bladder cancer. Its flagship product, Cxbladder, is a suite of genomic urine tests designed to provide non-invasive methods for detecting and managing bladder cancer. Pacific Edge operates through two segments: Commercial and Research. The Commercial segment focuses on the sale and marketing of Cxbladder, while the Research segment is dedicated to developing new diagnostic and prognostic tools for various cancers, including colorectal, gastric, endometrial cancers, and melanoma. Cxbladder includes several tests: Cxbladder Triage, Cxbladder Detect, Cxbladder Monitor, and Cxbladder Resolve. These tests assist in identifying patients at low probability of having bladder cancer, detecting bladder and other urinary tract cancers, monitoring for recurrence, and identifying those likely to have aggressive forms of bladder cancer. Pacific Edge has expanded its reach to New Zealand, the United States, Australia, and Singapore, aiming to establish Cxbladder as a standard diagnostic tool for urologists.

PFGTF的投资论点是什么？

Pacific Edge Limited presents a focused investment opportunity within the cancer diagnostics market, particularly in bladder cancer detection. The company's Cxbladder suite of genomic urine tests offers a non-invasive alternative to traditional methods. Key value drivers include the continued adoption of Cxbladder by urologists in the United States, Australia, New Zealand, and Singapore, as well as the successful development and commercialization of new diagnostic tools for other cancers, such as Cxcolorectal. The company's gross margin of 26.2% indicates potential for improved profitability as sales scale. Ongoing catalysts include expanding clinical utility and securing favorable reimbursement policies. Potential risks include competition from established diagnostic companies, regulatory hurdles, and the need for additional funding to support research and commercialization efforts. The company's negative P/E ratio of -4.78 and negative profit margin of -205.3% highlight the importance of achieving profitability through revenue growth and cost management.

PFGTF在哪个行业运营？

Pacific Edge operates within the medical diagnostics industry, a sector experiencing growth driven by advancements in genomic technologies and the increasing prevalence of cancer. The market is competitive, with established players like CORBF (Exact Sciences), LDXHF (Laboratory Corporation of America), ORXOF (Quest Diagnostics), PBIGF (PerkinElmer), and SHIEF (Siemens Healthineers) offering a range of diagnostic solutions. Pacific Edge differentiates itself through its focus on non-invasive urine-based cancer diagnostics, particularly for bladder cancer. The industry is characterized by stringent regulatory requirements, the need for continuous innovation, and the importance of securing reimbursement from healthcare providers.

Medical - Diagnostics & Research

Healthcare

PFGTF有哪些增长机遇？

Expansion in the United States: The US market represents a significant growth opportunity for Pacific Edge, driven by the high incidence of bladder cancer and the increasing adoption of non-invasive diagnostic methods. Securing favorable reimbursement policies and expanding the sales force in key regions could drive increased Cxbladder utilization. The US bladder cancer diagnostics market is estimated to be worth several billion dollars annually, providing a substantial addressable market.
Development of New Cancer Diagnostics: Pacific Edge is developing diagnostic tools for other cancers, including colorectal, gastric, endometrial cancers, and melanoma. Successful development and commercialization of these new products would diversify the company's revenue streams and expand its market reach. The market for colorectal cancer diagnostics, for example, is projected to reach $4.5 billion by 2027.
Strategic Partnerships: Collaborating with leading urology clinics and healthcare systems could accelerate the adoption of Cxbladder and provide access to a wider patient base. Strategic partnerships could also facilitate the development and commercialization of new diagnostic tools. These partnerships could involve joint research, co-marketing agreements, or distribution arrangements.
International Expansion: Expanding into new international markets, such as Europe and Asia, represents another growth opportunity for Pacific Edge. These markets have a growing demand for advanced cancer diagnostics and could benefit from the non-invasive nature of Cxbladder. Regulatory approvals and market access strategies would be critical for successful international expansion.
Increased Clinical Utility and Awareness: Generating additional clinical data to support the use of Cxbladder in various clinical settings could further drive adoption by urologists. Increasing awareness of Cxbladder among patients and healthcare providers through marketing and educational initiatives could also contribute to growth. This includes demonstrating the cost-effectiveness and improved patient outcomes associated with Cxbladder.

Market capitalization of $0.24 billion, reflecting its position as a smaller player in the diagnostics market.
Gross margin of 26.2%, indicating potential for profitability improvements with increased sales volume and cost management.
Negative P/E ratio of -4.78, suggesting the company is currently unprofitable.
Beta of 0.73, indicating lower volatility compared to the overall market.
Profit margin of -205.3%, highlighting the need for improved operational efficiency and revenue generation.

PFGTF提供哪些产品和服务？

Develop and commercialize diagnostic tools for early cancer detection.
Offer Cxbladder, a suite of genomic urine tests for bladder cancer detection and management.
Provide non-invasive methods for detecting and monitoring bladder cancer.
Develop diagnostic products for colorectal, gastric, endometrial cancers, and melanoma.
Operate in the Commercial and Research segments.
Focus on early detection and management of cancers in New Zealand, the United States, Australia, and Singapore.

PFGTF如何赚钱？

Generate revenue through the sale of Cxbladder tests to urologists and healthcare providers.
Focus on commercializing diagnostic tools developed through research and development efforts.
Seek reimbursement from healthcare providers and insurance companies for Cxbladder tests.
Expand market reach through strategic partnerships and international expansion.

Urologists and other healthcare providers involved in the diagnosis and management of bladder cancer.
Patients at risk of or diagnosed with bladder cancer.
Hospitals and clinics offering cancer diagnostic services.
Research institutions and pharmaceutical companies involved in cancer research.

Proprietary genomic urine test technology for bladder cancer detection.
Established presence in the bladder cancer diagnostics market with Cxbladder.
Focus on non-invasive diagnostic methods, offering advantages over traditional invasive procedures.
Expanding portfolio of diagnostic tools for various cancers.

什么因素可能推动PFGTF股价上涨？

Upcoming: Publication of new clinical data supporting the use of Cxbladder.
Ongoing: Expansion of Cxbladder sales in the United States and other key markets.
Ongoing: Development and commercialization of new cancer diagnostic tools.
Upcoming: Securing favorable reimbursement policies for Cxbladder from healthcare providers.
Ongoing: Strategic partnerships with healthcare providers and research institutions.

PFGTF的主要风险是什么？

Potential: Competition from established diagnostic companies with greater resources.
Potential: Regulatory hurdles and changes in reimbursement policies.
Potential: Technological advancements that could render Cxbladder obsolete.
Ongoing: Reliance on Cxbladder as the primary revenue source.
Ongoing: Negative profitability and need for additional funding.

PFGTF的核心优势是什么？

Proprietary Cxbladder technology for non-invasive bladder cancer detection.
Established presence in key markets, including the United States, Australia, and New Zealand.
Focus on early cancer detection and management.
Developing diagnostic tools for multiple cancer types.

PFGTF的劣势是什么？

Negative profitability and reliance on external funding.
Limited market share compared to larger diagnostic companies.
Dependence on Cxbladder as the primary revenue source.
Exposure to regulatory and reimbursement risks.

PFGTF有哪些机遇？

Expansion in the United States and other international markets.
Development and commercialization of new cancer diagnostic tools.
Strategic partnerships with healthcare providers and research institutions.
Increasing awareness and adoption of non-invasive cancer diagnostics.

PFGTF面临哪些威胁？

Competition from established diagnostic companies.
Regulatory hurdles and changes in reimbursement policies.
Technological advancements that could render Cxbladder obsolete.
Economic downturns that could reduce healthcare spending.

PFGTF的竞争对手是谁？

Exact Sciences — Offers Cologuard, a non-invasive colon cancer screening test. — (CORBF)
Laboratory Corporation of America — Provides a wide range of diagnostic testing services, including cancer diagnostics. — (LDXHF)
Quest Diagnostics — Offers a comprehensive suite of diagnostic testing services. — (ORXOF)
PerkinElmer — Develops and markets diagnostic and research solutions. — (PBIGF)
Siemens Healthineers — Offers a broad portfolio of medical imaging, laboratory diagnostics, and healthcare IT solutions. — (SHIEF)

Key Metrics

MoonshotScore: 52/100

Company Profile

CEO: Peter Meintjes
Headquarters: Dunedin, NZ
Employees: 114
Founded: 2016

AI Insight

AI analysis pending for PFGTF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Pacific Edge Limited do?

Pacific Edge Limited is a cancer diagnostic company specializing in the development and commercialization of diagnostic and prognostic tools for the early detection and management of cancers. Their primary product, Cxbladder, is a suite of genomic urine tests designed for the non-invasive detection and management of bladder cancer. The company operates in the Commercial and Research segments, focusing on expanding the use of Cxbladder and developing new diagnostic solutions for various cancers.

What do analysts say about PFGTF stock?

AI analysis is currently pending for PFGTF, so analyst consensus is unavailable at this time. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Key valuation metrics to consider include the company's market capitalization, revenue growth, gross margin, and profitability. Growth considerations include the company's ability to expand Cxbladder sales, develop new diagnostic tools, and secure favorable reimbursement policies.

What are the main risks for PFGTF?

The main risks for Pacific Edge Limited include competition from established diagnostic companies, regulatory hurdles, and changes in reimbursement policies. The company also faces the risk of technological advancements that could render Cxbladder obsolete. Additionally, Pacific Edge is currently unprofitable and relies on external funding, which could pose a challenge if the company is unable to secure additional capital. Investing in OTC stocks carries additional risks, including limited financial disclosure and lower liquidity.